Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases


NCT01442935

Interventional

Phase 2

Active, not recruiting
The main objective is to compare resection rates (R0 or R1) for hepatic metastases in the experimental arm (tri chemotherapy plus targeted therapy) versus the control arm (bi chemotherapy plus targeted therapy); in both arms the targeted therapy is selected according to K-Ras status of the patient's tumor. The secondary objectives are to evaluate the objective response rate (CR and PR) after 4 cycles of treatment, according the RECIST V1.1 evaluation scale. - the rate of complete remission (CR) at 6 months after the last study treatment (hepatic surgery or last chemotherapy cycle). - the specific rates of resection R0, R1, R2. - the complete pathological response Rate, - the relapse-free survival rate in (R0 or R1) resected patients, - the response duration in non-resected patients, - the toxicity according to CTC AE V4 scale except for the neurotoxicity that will be evaluated with the Levi scale, - the post operative complications using the DINDO classification, - the progression-free survival (PFS) and overall survival (OS). The objectives of the biological study are: - to evaluate tumor-related predictive factors such as somatic mutations (KRAS, BRAF, TP53) and genetic amplification related factors (EGFR), - to evaluate patient-related predictive factors in connection with genetic polymorphisms (Fc gamma and VEGF receptors), - to evaluate ADCC activity via immunohistochemistry in order to analyze the lympho free and progression-free survival, - to study circulating of tumor cells as prognostic factor for metastatic colorectal cancer, non- resectable at presentation.
Feb 28,2011
All
18 Years
N/A
256

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.